We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Longitudinal Changes in Epigenetic Age Acceleration in Aviremic Human Immunodeficiency Virus-Infected Recipients of Long-term Antiretroviral Treatment.
- Authors
Esteban-Cantos, Andrés; Montejano, Rocio; Rodríguez-Centeno, Javier; Saiz-Medrano, Gabriel; Miguel, Rosa De; Barruz, Pilar; Bernardino, Jose I; Mena-Garay, Beatriz; Cadiñanos, Julen; Jiménez-González, María; Nevado, Julián; Valencia, Eulalia; Mayoral-Muñoz, Mario; Arribas, Jose R; Rodés, Berta; De Miguel, Rosa
- Abstract
<bold>Background: </bold>Human immunodeficiency virus (HIV) infection induces epigenetic age acceleration (EAA), but it remains unclear whether epigenetic aging continues to accelerate during successful antiretroviral therapy (ART) and prolonged virological suppression.<bold>Methods: </bold>We longitudinally analyzed 63 long-term aviremic HIV-infected adults. Using blood DNA methylation patterns, we calculated EAA measures based on 3 epigenetic clocks (Horvath's clock, PhenoAge, and GrimAge). We recorded the emergence of serious AIDS-related and non-AIDS-related events throughout the study to assess its association with EAA.<bold>Results: </bold>All participants were on stable ART and were virologically suppressed. After 4 years of follow-up, PhenoAge-EAA and GrimAge-EAA showed no differences, whereas Horvath-EAA slightly decreased (median difference, -0.53 years; P = .015). Longitudinal changes in EAA measures were independent of changes in CD4 cell counts, the ART regimen, or other HIV-related factors. Nineteen percent of participants experienced a serious clinical event during the study. Horvath-EAA was significantly higher at baseline in participants with clinical events (P = .027). After adjusting for confounders, we found a trend toward an association of higher levels of all EAA measures at baseline with serious clinical events.<bold>Conclusions: </bold>Epigenetic aging did not accelerate in long-term aviremic HIV-infected adults after 4 years of successful ART. EAA measures deserve further study as potential tools for predicting clinical events.
- Subjects
ANTIRETROVIRAL agents; HIV; EPIGENETICS; CD4 lymphocyte count; IMMUNODEFICIENCY
- Publication
Journal of Infectious Diseases, 2022, Vol 225, Issue 2, p287
- ISSN
0022-1899
- Publication type
journal article
- DOI
10.1093/infdis/jiab338